Robert Davis - Integra LifeSciences President
| IART Stock | USD 24.24 0.66 2.80% |
President
Mr. Robert T. Davis, Jr. Corporationrationrate Vice President, President Orthopedics and Tissue Technologies of the Company effective December 1, 2016. Mr. Davis is responsible for the management of the Orthopedics and Tissue Technologies global division, which includes orthopedic extremity implants, and regenerative tissue products. His responsibilities include leadership of sales, commercial operations, marketing and strategy, product development, regulatory affairs, quality assurance, manufacturing services and repair, and business development of the orthopedic extremity implants and regenerative tissue portfolio. Mr. Davis joined Integra in July 2012 as President of the Global Neurosurgery business and was appointed Integras Corporationrationrate Vice President in December 2012 and President Specialty Surgical Solutions in 2014. He brings more than 25 years of executive management experience in the global healthcare industry. Prior to joining Integra, Mr. Davis was the General Manager for the Global Anesthesia Critical Care business at Baxter Healthcare, from 2009 to 2012, and held various general management positions at GE Healthcare in the areas of interventional therapeutics, cardiovascular imaging and diagnostic ultrasound from 1997 to 2009 since 2016.
| Age | 65 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 1100 Campus Road, Princeton, NJ, United States, 08540 |
| Phone | 609 275 0500 |
| Web | https://www.integralife.com |
Integra LifeSciences Management Efficiency
The company has return on total asset (ROA) of 0.0302 % which means that it generated a profit of $0.0302 on every $100 spent on assets. This is way below average. Integra LifeSciences' management efficiency ratios could be used to measure how well Integra LifeSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.04 in 2024. Return On Capital Employed is likely to gain to 0.03 in 2024. At this time, Integra LifeSciences' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2 B in 2024, whereas Total Current Liabilities is likely to drop slightly above 158.9 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jacqueline Scanlan | Haemonetics | 46 | |
| Virginia Sanzone | ICU Medical | 49 | |
| Patrick Beyer | CONMED | 58 | |
| Peter Shagory | CONMED | 55 | |
| James Darecca | Haemonetics | 50 | |
| David Murray | CONMED | 76 | |
| Stewart Strong | Haemonetics | 57 | |
| Michelle Basil | Haemonetics | 52 | |
| Daniel Jonas | CONMED | 56 | |
| Terence Berge | CONMED | 54 | |
| Heather Cohen | CONMED | 51 | |
| Todd Garner | CONMED | 55 | |
| Anila Lingamneni | Haemonetics | 57 | |
| William Burke | Haemonetics | 52 | |
| Stanley Peters | CONMED | 45 | |
| Daniel Woolson | ICU Medical | 47 | |
| Joseph Wright | Merit Medical Systems | 54 | |
| Johonna Pelletier | CONMED | 51 | |
| John Kennedy | CONMED | 66 | |
| Stanley III | CONMED | 49 | |
Management Performance
| Return On Equity | -0.0042 | ||||
| Return On Asset | 0.0302 |
Integra LifeSciences Leadership Team
Elected by the shareholders, the Integra LifeSciences' board of directors comprises two types of representatives: Integra LifeSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Integra. The board's role is to monitor Integra LifeSciences' management team and ensure that shareholders' interests are well served. Integra LifeSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Integra LifeSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Burhop, Chief Scientific Officer, Corporate Vice President | ||
| Ruth Fleming, Vice Marketing | ||
| Eric Schwartz, Corporate Vice President General Counsel, Secretary | ||
| Lea Knight, Executive CFO | ||
| Mathieu Aussermeier, Investor Finance | ||
| Robert Davis, President of Specialty Surgical Solutions and Corporate VP | ||
| Maria Platsis, Sr Devel | ||
| William Compton, Chief VP | ||
| Chantal VeillonBerteloot, Executive Officer | ||
| Jeffrey Mosebrook, Principal Accounting Officer, Vice President Corporate Controller | ||
| Susan Krause, Corporate Officer | ||
| Stuart Hart, Corporate Officer | ||
| Mark Jesser, Corporate Officer | ||
| Jan Witte, CEO President | ||
| Laurene Isip, Vice Relations | ||
| Michael McBreen, Executive Surgical | ||
| Carrie Anderson, CFO and Principal Financial Officer, Corporate Vice President | ||
| Eric JD, Chief VP | ||
| Stuart Essig, Chairman of the Board | ||
| Jessica Smith, Corporate Officer | ||
| Stephen Leonard, Corporate Chain |
Integra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Integra LifeSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0042 | ||||
| Return On Asset | 0.0302 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 3.53 B | ||||
| Shares Outstanding | 77.16 M | ||||
| Shares Owned By Insiders | 3.21 % | ||||
| Shares Owned By Institutions | 93.27 % | ||||
| Number Of Shares Shorted | 5.18 M | ||||
| Price To Earning | 26.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.